Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide

Muzzi, Alessandro; Brozzi, Alessandro; Serino, Laura; Bodini, Margherita; Abad, Raquel; Caugant, Dominique A.; Comanducci, Maurizio; Lemos, Ana Paula Silva de; Gorla, Maria Cecília Outeiro; Křížová, Pavla; Mikula, Claudia; Mulhall, Robert M.; Nissen, Michael D.; Nohynek, Hanna; Simões, Maria João; Skoczyńska, Anna; Stefanelli, Paola; Taha, Muhamed‐Kheir; Toropainen, Maija; Tzanakaki, Georgina; Vadivelu-Pechai, Kumaran; Watson, Philip; Vázquez, Julio; Rajam, Gowrisankar; Rappuoli, Rino; Borrow, Ray; Medini, Duccio

doi:10.1016/j.vaccine.2018.12.061

Cited by 68 publications

(89 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as the pathogen continues to evolve, potential changes in the antigen expression of circulating strains are anticipated. Data so far are encouraging, with 4CMenB maintaining consistent coverage worldwide and over time, as predicted by MATS (Muzzi et al, 2019) and confirmed by field effectiveness data from the UK, where a 60% reduction in the estimated number of cases of MenB IMD in infants was observed in the third year of the 4CMenB vaccination program (Joint Committee on Vaccination and Immunisation (JCVI), 2018).…”

Section: Cmenb Universal Mass Vaccination-challenges and Opportunitiesmentioning

confidence: 63%

“…MATS-based estimates of 4CMenB coverage range from 68% to 89% in European countries and from 66% to 91% in Australia, Canada, Brazil, and the USA (Abad et al, 2016;Medini et al, 2015;Parikh et al, 2017;Rajam et al, 2017;Simoes et al, 2017;Tzanakaki et al, 2014;Vogel et al, 2013;Wasko et al, 2016), with an overall estimated coverage of 81% calculated for a sample size of 3912 invasive MenB strains, collected from 17 different countries (Muzzi et al, 2019). Antibodies induced by the NHBA and fHbp components of 4CMenB have been consistently observed to make the highest contribution to coverage.…”

Section: Contribution Of Individual 4cmenb Antigens To the Coverage Omentioning

confidence: 99%

“…NadA is an auto-transporter adhesin believed to play an important role in nasopharyngeal colonization and bacterial invasion (Capecchi et al, 2005). Recent data showed that 27% of IMD MenB isolates, collected from 17 different countries between 2000 and 2016, harbored the NadA gene (Muzzi et al, 2019). However, this may vary over time and by geographic region.…”

Section: Role and Contribution Of Fhbpmentioning

confidence: 99%

“…The development of 4CMenB by reverse vaccinology to identify potential antigens based on their level of expression and surface localization/secretion constituted an important success in the effort to control and prevent meningococcal disease. The vaccine has already demonstrated broad coverage against clinically relevant MenB strains (Muzzi et al, 2019) and has been implemented in the national immunization program in the UK, Ireland, and Italy. However, as the pathogen continues to evolve, potential changes in the antigen expression of circulating strains are anticipated.…”

Section: Cmenb Universal Mass Vaccination-challenges and Opportunitiesmentioning

confidence: 99%

See 3 more Smart Citations

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease

Watson

Novy

Friedland

2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Section: Cmenb Universal Mass Vaccination-challenges and Opportunitiesmentioning

confidence: 63%

Section: Contribution Of Individual 4cmenb Antigens To the Coverage Omentioning

confidence: 99%

Section: Role and Contribution Of Fhbpmentioning

confidence: 99%

Section: Cmenb Universal Mass Vaccination-challenges and Opportunitiesmentioning

confidence: 99%

See 2 more Smart Citations

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease

Watson

Novy

Friedland

2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

“…The use of MATS and MEASURE assays to estimate the strain coverage of MenB vaccines has a number of limitations, such as the inability to evaluate non-culture cases and limited availability for reference laboratories to be able to perform the assays. As a result, Genetic Meningococcal Antigen Typing System (gMATS) 67 has been developed to assess strain coverage of 4CMenB in culture and potentially non-culture cases. gMATS was developed using a large international genotypic/MATS dataset ( n = 3481 isolates) to assign antigen peptides to covered, not covered or unpredictable (half of which are considered covered within national strain panel datasets).…”

Section: Determination Of Strain Coverage Of Serogroup B Vaccinesmentioning

confidence: 99%

Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Bai

Borrow

Bukovski

et al. 2019

Journal of Infection

Self Cite

View full text Add to dashboard Cite

The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at < 1 case per 10 0,0 0 0 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk * Corresponding author.

show abstract

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal

Rodrigues

Marlow

Simões

et al. 2020

JAMA

Self Cite

View full text Add to dashboard Cite

IMPORTANCE A 4-component meningococcus group B vaccine (4CMenB) is the only vaccine in use to prevent group B invasive meningococcal disease in young children, but no matched controlled studies have evaluated it. OBJECTIVE To determine the association between receipt of 4CMenB and invasive group B meningococcal disease. DESIGN, SETTING, AND PARTICIPANTS Matched incidence density case-control study. Patients presenting from October 2014 to March 2019 were ascertained, with follow-up until death or discharge (last follow-up in June 2019) in 31 pediatric services in Portugal. Children and adolescent residents in Portugal with laboratory-confirmed invasive meningococcal disease were included. Controls, usually 2 per case, with unrelated conditions who were at the same hospital at the same time were matched for sex, age, and residence. EXPOSURES Immunization with 4CMenB, ascertained from the national database (2-4 doses are recommended, depending on age). MAIN OUTCOMES AND MEASURESThe primary outcome was group B invasive meningococcal disease in fully vaccinated cases compared with controls. The secondary outcomes were all serogroup invasive meningococcal disease in fully vaccinated cases compared with controls and group B and all serogroup invasive meningococcal disease in cases compared with controls who received at least 1 vaccine dose. RESULTSOf 117 patients with invasive meningococcal disease, 98 were eligible for inclusion and 82 had group B invasive meningococcal disease; 69 were old enough to have been fully vaccinated and considered protected. Among these 69 cases, the median (interquartile range) age was 24 (4.5-196) months, 42 were male, and the median (interquartile range) duration of hospitalization was 8 (0-86) days. Five of 69 cases (7.2%) and 33 of 142 controls (23.1%) were fully vaccinated (difference, −16.0% [95% CI, −26.3% to −5.7%]; odds ratio [OR], 0.21 [95% CI, 0.08-0.55]). For all serogroup invasive meningococcal disease, 6 of 85 cases (7.1%) and 39 of 175 controls (22.3%) were fully vaccinated (difference, −15.2% [95% CI, −24.3% to −6.1%]; OR, 0.22 [95% CI, 0.09-0.53]). For group B disease, 8 of 82 cases (9.8%) and 50 of 168 controls (29.8%) received at least 1 vaccine dose (difference, −20.0% [95% CI, −30.3% to −9.7%]; OR, 0.18 [95% CI, 0.08-0.44]) and for all serogroup invasive meningococcal disease, 11 of 98 cases (11.2%) and 61 of 201 controls (30.3%) received at least 1 vaccine dose (difference, −19.1% [95% CI, −28.8% to −9.5%]; OR, 0.23 [95% CI, 0.11-0.49]). CONCLUSIONS AND RELEVANCEDuring the first 5 years of vaccine availability in Portugal, vaccination with 4CMenB was less likely among children who developed invasive meningococcal disease compared with matched controls without invasive meningococcal disease. These findings may help inform the use of the 4CMenB vaccine in clinical practice.

show abstract

Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide

Cited by 68 publications

References 37 publications

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease

Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal

Contact Info

Product

Resources

About